Femasys Inc (FEMY) Stock Price, Quote & News

Company Profile

Femasys Inc., a biomedical company, develops and commercializes therapeutic and diagnostic products for women's reproductive health needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination device; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemSperm, a sperm handling kit; FemChec, a confirmation test for tubal patency; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; and FemCath, a cornual b...

Industry: Medical Instruments & Supplies

Sector: Healthcare

Phone: 770 500 3910

Fax: 404 581 5903

Website: femasys.com

Address:

3950 Johns Creek Court, Suite 100, Suwanee, United States

TripTrap Jul. 19 at 11:54 PM

$FEMY Yes… i’ve disappeared… Bub-bye stiffy! I’m not going anywhere, but have resolved that this is going to be a much longer hold than I thought. Next earnings, I believe come out mid August but hopefully we get some kind of news before then.

0 · Reply

steve04240 Jul. 19 at 8:46 PM

$FEMY buyout candidate LETS GO!!!!!

0 · Reply

Severian1 Jul. 18 at 3:31 PM

$FEMY under 10 mil market cap. for a company selling products! there are so many biotechs with zero revenue that are destroying this one in market cap. no interest equals no money

0 · Reply

onethestiff Jul. 18 at 5:12 AM

$FEMY going down and down! Was The pumper Trip Trap disappeared too?

2 · Reply

Ked1977 Jul. 17 at 8:09 PM

$FEMY they only respond with read our press releases.

0 · Reply

Five555 Jul. 17 at 8:04 PM

$FEMY what's up with a class action fem crooks

0 · Reply

steve04240 Jul. 17 at 7:38 PM

$FEMY 3 is the new 4🤮

0 · Reply

4RiskyBusiness4 Jul. 17 at 6:54 PM

$FEMY Always darkest before dawn. Steady lads.

2 · Reply

Severian1 Jul. 17 at 5:26 PM

$FEMY this was a foregone conclusion after a r/s. happens 95 percent of the time. If youre a true believer you still should have sold before split and bought back in after this obvious drop

1 · Reply

Zaksab Jul. 17 at 5:15 PM

$FEMY has any shareholder made a subtle enquiry to management about the state of the p&l….

0 · Reply

Femasys regains compliance with Nasdaq

Jun 24, 2026, 9:00 AM EDT - 26 days ago

Femasys Regains Compliance with Nasdaq Listing Requirements

2026-06-05T23:55:32.000Z - 6 weeks ago

Femasys Inc trading halted, news pending

2026-05-13T14:46:53.000Z - 2 months ago

Femasys announces CE Mark approval for FemHSG Catheter

May 13, 2026, 9:00 AM EDT - 2 months ago

Femasys Expands Fertility Care Portfolio in Europe with CE Mark Approval for FemHSG™ Catheter

May 13, 2026, 7:00 AM EDT - 2 months ago

Femasys Slides: Corporate presentation

May 8, 2026, 4:05 PM EDT - 2 months ago

Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update

May 8, 2026, 8:00 AM EDT - 2 months ago

Femasys Quarterly report: Q1 2026

May 8, 2026, 8:00 AM EDT - 2 months ago

Femasys Earnings release: Q1 2026

May 5, 2026, 9:00 AM EDT - 2 months ago

Femasys Enables OB/GYNs to Deliver First-Line Fertility Treatment with Initial Commercial Use of FemaSeed® Complete

Apr 30, 2026, 8:00 AM EDT - 2 months ago

Femasys Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 2 months ago

Femasys Proxy statement: Proxy filing

2026-04-16T13:56:18.000Z - 3 months ago

Femasys drives growth with Israeli market entry for fertility portfolio

Apr 6, 2026, 8:00 AM EDT - 3 months ago

Femasys Proxy statement: Proxy filing

Mar 31, 2026, 4:05 PM EDT - 3 months ago

Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update

Mar 31, 2026, 8:00 AM EDT - 3 months ago

Femasys Annual report: Q4 2025

Mar 31, 2026, 8:00 AM EDT - 3 months ago

Femasys Earnings release: Q4 2025

Mar 27, 2026, 8:00 AM EDT - 4 months ago

Femasys Proxy statement: Proxy filing

2026-03-24T15:20:53.000Z - 4 months ago

Femasys management to meet virtually with Lake Street

2026-03-18T13:05:27.000Z - 4 months ago

Femasys appoints Kenneth Eichenbaum to its Board of Directors

2026-03-10T13:17:37.000Z - 4 months ago

Femasys advances FemBloc to U.S. approval with initiation of trial enrollment

2026-03-03T13:13:48.000Z - 4 months ago

Femasys initiated with a Buy at Lake Street

Feb 27, 2026, 5:26 PM EST - 5 months ago

Femasys Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-02-26T14:06:51.000Z - 5 months ago

Femasys FemBloc achieved certification under MDSAP

2026-02-23T14:06:46.000Z - 5 months ago

Femasys receives AMA CPT Editorial Panel approval for new CPT code

Feb 23, 2026, 9:00 AM EST - 5 months ago

Femasys Receives AMA CPT Editorial Panel Approval for New Category III CPT Code for FemaSeed Intratubal Insemination

2026-02-03T14:20:28.000Z - 5 months ago

Femasys enters distribution partnership with OR Consulting

2026-01-14T14:15:55.000Z - 6 months ago

Femasys granted 180-day extension by Nasdaq to regain compliance

2026-01-13T14:05:24.000Z - 6 months ago

Femasys announces partnership with Refuah Health Center

Jan 13, 2026, 9:00 AM EST - 6 months ago

Femasys Announces Partnership with Refuah Health Center to Expand First-Line Access to FemaSeed® in Community-Based Care

2025-12-31T21:40:10.000Z - 7 months ago

Femasys files to sell 68.42M shares of common stock for holders

Dec 31, 2025, 7:00 AM EST - 7 months ago

Femasys Registration statement: Registration filing

2025-12-18T14:21:29.000Z - 7 months ago

Femasys secures U.S. FDA clearance for FemVue Controlled device

Dec 18, 2025, 9:15 AM EST - 7 months ago

Femasys Secures U.S. FDA Clearance for Next-Generation FemVue Diagnostic Device

Dec 4, 2025, 7:00 AM EST - 8 months ago

Femasys Registration statement: Registration filing

2025-11-25T14:25:20.000Z - 8 months ago

PharmaCyte sells Femasys stake, sees cash position rising to $20M

PMCB

Nov 25, 2025, 9:15 AM EST - 8 months ago

PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment

PMCB

2025-11-20T10:00:27.000Z - 8 months ago

Femasys initiated with a Buy at Laidlaw

Nov 14, 2025, 7:00 AM EST - 8 months ago

Femasys Quarterly report: Q3 2025

Nov 14, 2025, 7:00 AM EST - 8 months ago

Femasys Earnings release: Q3 2025

2025-11-10T14:16:39.000Z - 9 months ago

Femasys advances global growth with second partner order for FemBloc in Europe

2025-11-03T13:40:39.000Z - 9 months ago

Femasys secures FDA approval to advance final FemBloc trial phase

Nov 3, 2025, 8:30 AM EST - 9 months ago

Femasys Secures FDA Approval to Advance Final FemBloc® Trial Phase and $12 Million Financing, with Potential to Reach $58 Million

Oct 16, 2025, 9:00 AM EDT - 9 months ago

Femasys to Exhibit at the ASRM 2025 Scientific Congress & Expo

Sep 11, 2025, 9:00 AM EDT - 11 months ago

Femasys Expands FemSperm™ Product Line with New Insemination Prep Kit to Broaden Gynecology-Based Access to FemaSeed®

Sep 8, 2025, 9:00 AM EDT - 11 months ago

Femasys Secures Regulatory Approval for FemBloc® Permanent Birth Control in New Zealand

Aug 25, 2025, 11:44 PM EDT - 11 months ago

Femasys Announces Pricing of $8.0 Million Underwritten Public Offering

Aug 21, 2025, 8:00 AM EDT - 11 months ago

Femasys Registration statement: Registration filing

Aug 20, 2025, 8:00 AM EDT - 11 months ago

Femasys Registration statement: Registration filing

Aug 8, 2025, 4:05 PM EDT - 1 year ago

Femasys Announces Second Quarter Financial Results for 2025

Aug 8, 2025, 8:00 AM EDT - 1 year ago

Femasys Quarterly report: Q2 2025

Aug 8, 2025, 8:00 AM EDT - 1 year ago

Femasys Earnings release: Q2 2025

Aug 6, 2025, 9:00 AM EDT - 1 year ago

Femasys Secures First European Order for FemBloc, Marking Strategic Milestone in Global Expansion

Jul 3, 2025, 8:00 AM EDT - 1 year ago

Femasys Registration statement: Registration filing

Jul 1, 2025, 9:00 AM EDT - 1 year ago

Femasys Achieves Australian and New Zealand Regulatory Approvals for FemaSeed® for First-Line Infertility Treatment and FemVue Diagnostic

Jun 25, 2025, 9:00 AM EDT - 1 year ago

Femasys Announces Historic Milestone with European Approval of FemBloc®, the First Non-Surgical Permanent Birth Control

Jun 17, 2025, 9:00 AM EDT - 1 year ago

Femasys Names New Chief Commercial Officer to Drive Execution and Global Growth

Jun 11, 2025, 9:00 AM EDT - 1 year ago

Femasys Announces Partnership with Carolinas Fertility Institute, One of America's Best Fertility Clinics, to Offer FemaSeed® in its More than 8 Locations

May 29, 2025, 4:23 PM EDT - 1 year ago

Femasys Announces Proposed Public Offering of Common Stock and Concurrent Private Placement

May 8, 2025, 5:01 PM EDT - 1 year ago

Femasys Announces Financial Results for Quarter Ended March 31, 2025, and Provides Corporate Update

May 8, 2025, 8:00 AM EDT - 1 year ago

Femasys Quarterly report: Q1 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Femasys Earnings release: Q1 2025

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Femasys Proxy statement: Proxy filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Femasys Proxy statement: Proxy filing

Mar 27, 2025, 9:00 AM EDT - 1 year ago

Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update

Mar 27, 2025, 8:00 AM EDT - 1 year ago

Femasys Annual report: Q4 2024

Mar 27, 2025, 8:00 AM EDT - 1 year ago

Femasys Earnings release: Q4 2024

Mar 19, 2025, 9:20 AM EDT - 1 year ago

Femasys Announces Partnership with CNY Fertility, National Conglomerate Network of Fertility Centers, to Offer FemaSeed in its 11 Locations

Mar 18, 2025, 9:00 AM EDT - 1 year ago

Femasys Secures Distribution Partnerships for Commercialization of FemBloc® in Spain

Mar 13, 2025, 8:30 AM EDT - 1 year ago

Femasys Announces FemBloc Delivery System Approval in Europe; A Significant Step Towards FemBloc Permanent Birth Control Availability as the First-Ever Non-Surgical Approach

Feb 25, 2025, 9:20 AM EST - 1 year ago

Femasys Announces Peer-Reviewed Publication of Positive Safety and Efficacy Results from FemBloc® Permanent Birth Control Clinical Trials

Feb 11, 2025, 9:00 AM EST - 1 year ago

Femasys Announces UK Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic Devices

Jan 30, 2025, 8:30 AM EST - 1 year ago

Femasys Announces Notices of Intention to Grant for Two New European Patent Applications Covering Use of FemBloc Permanent Birth Control

Jan 16, 2025, 8:30 AM EST - 1 year ago

Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemaSeed® for Female Infertility Treatment

Nov 26, 2024, 8:30 AM EST - 1 year ago

Femasys Announces Peer-Reviewed Publication of Positive Data from Prospective, Multicenter Pivotal Trial of FemaSeed® Infertility Treatment

Nov 12, 2024, 8:30 AM EST - 1 year ago

Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update

Nov 12, 2024, 7:00 AM EST - 1 year ago

Femasys Quarterly report: Q3 2024

Nov 12, 2024, 7:00 AM EST - 1 year ago

Femasys Earnings release: Q3 2024

Nov 1, 2024, 8:30 AM EDT - 1 year ago

Femasys Announces Issued U.S. Patent Covering FemBloc® Device for Female Permanent Birth Control

Oct 10, 2024, 8:30 AM EDT - 1 year ago

Femasys to Exhibit at ASRM 2024 and Participate in the Congress' KEEPR Education Program

Oct 2, 2024, 8:30 AM EDT - 1 year ago

Femasys Receives Second Order from Spain Partners After Successfully Completing Commercial FemaSeed® Infertility Treatments

Sep 18, 2024, 8:30 AM EDT - 1 year ago

Femasys Announces Infertility Clinic Customers from Coast to Coast

Sep 11, 2024, 8:30 AM EDT - 2 years ago

Femasys Secures Strategic Distribution Partnerships for Commercialization of FemaSeed® for over $1.3M in Spanish Market

Sep 9, 2024, 8:30 AM EDT - 2 years ago

Femasys Inc. Receives U.S. FDA Clearance to Market FemChec®, an Innovative Diagnostic Solution for Fallopian Tube Check

Sep 5, 2024, 8:30 AM EDT - 2 years ago

Femasys to Exhibit at The Canadian Fertility and Andrology Society's 70th Annual Meeting

Sep 3, 2024, 8:30 AM EDT - 2 years ago

Femasys to Participate in Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 29, 2024, 8:30 AM EDT - 2 years ago

Femasys Announces CE Mark and Canadian Approval for FemVue® MINI, a Fallopian Tube Assessment Solution

Aug 27, 2024, 8:30 AM EDT - 2 years ago

Femasys Hosts Congresswoman Lucy McBath at Georgia Headquarters

Aug 8, 2024, 8:30 AM EDT - 2 years ago

Femasys Announces Financial Results for Quarter Ended June 30, 2024 and Provides Corporate Update

Aug 8, 2024, 8:00 AM EDT - 2 years ago

Femasys Quarterly report: Q2 2024

Aug 8, 2024, 8:00 AM EDT - 2 years ago

Femasys Earnings release: Q2 2024

Jun 27, 2024, 8:30 AM EDT - 2 years ago

Femasys to Participate in European Society of Human Reproduction and Embryology 40th Annual Meeting in Amsterdam

Jun 7, 2024, 8:00 AM EDT - 2 years ago

Femasys Proxy statement: Proxy filing

May 17, 2024, 8:30 AM EDT - 2 years ago

Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House's Office of Science and Technology Policy to Discuss the Cancer Moonshot Initiative

May 16, 2024, 8:30 AM EDT - 2 years ago

Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House's Gender Policy Council

May 9, 2024, 8:30 AM EDT - 2 years ago

Femasys Announces Financial Results for Quarter Ended March 31, 2024 and Provides Corporate Update

May 9, 2024, 8:00 AM EDT - 2 years ago

Femasys Quarterly report: Q1 2024

May 9, 2024, 8:00 AM EDT - 2 years ago

Femasys Earnings release: Q1 2024

May 7, 2024, 8:30 AM EDT - 2 years ago

Femasys Expands Commercial Management Team with Addition of Experienced New Hires

Apr 18, 2024, 8:30 AM EDT - 2 years ago

Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women's Healthcare Initiatives

TripTrap Jul. 19 at 11:54 PM

0 · Reply

steve04240 Jul. 19 at 8:46 PM

$FEMY buyout candidate LETS GO!!!!!

0 · Reply

Severian1 Jul. 18 at 3:31 PM

$FEMY under 10 mil market cap. for a company selling products! there are so many biotechs with zero revenue that are destroying this one in market cap. no interest equals no money

0 · Reply

onethestiff Jul. 18 at 5:12 AM

$FEMY going down and down! Was The pumper Trip Trap disappeared too?

2 · Reply

Ked1977 Jul. 17 at 8:09 PM

$FEMY they only respond with read our press releases.

0 · Reply

Five555 Jul. 17 at 8:04 PM

$FEMY what's up with a class action fem crooks

0 · Reply

steve04240 Jul. 17 at 7:38 PM

$FEMY 3 is the new 4🤮

0 · Reply

4RiskyBusiness4 Jul. 17 at 6:54 PM

$FEMY Always darkest before dawn. Steady lads.

2 · Reply

Severian1 Jul. 17 at 5:26 PM

$FEMY this was a foregone conclusion after a r/s. happens 95 percent of the time. If youre a true believer you still should have sold before split and bought back in after this obvious drop

1 · Reply

Zaksab Jul. 17 at 5:15 PM

$FEMY has any shareholder made a subtle enquiry to management about the state of the p&l….

0 · Reply

steve04240 Jul. 17 at 4:56 PM

$FEMY buy more or sell it all???

0 · Reply

dongknotts Jul. 17 at 4:46 PM

$FEMY Anybody think this is a buy at this low or is it heading for new lows?

2 · Reply

steve04240 Jul. 17 at 4:16 PM

$FEMY fuck you Kathy Fuck you FEMY

0 · Reply

4RiskyBusiness4 Jul. 17 at 3:51 PM

$FEMY Yawn.

0 · Reply

steve04240 Jul. 17 at 11:43 AM

$FEMY friggen DO SOMETHING WITH ALL THESE WONDERFUL PRODUCTS ??????🤬 At least communicate with your shareholders every now and again!?

1 · Reply

steve04240 Jul. 16 at 9:32 PM

$FEMY now im pissed

2 · Reply

NEWBIGTECH Jul. 16 at 6:30 PM

$NLST $FEMY

0 · Reply

Itzana Jul. 16 at 6:08 PM

$FEMY it’s worth 15 cents now. 😬

1 · Reply

Severian1 Jul. 16 at 3:55 PM

$FEMY just remember: with their products being so great, share price doesnt matter!!!! 🤡🤡🤡

0 · Reply

beaches911 Jul. 16 at 3:46 PM

$FEMY the stupidity of this ceo knows no bounds, she raises less than a years funds at a time forcing the stock to crash again and again. The next raise will be at $2 and it will be soon as they must be close to out of funds now

0 · Reply

Bluesir Jul. 16 at 12:03 PM

$FEMY Well, not only 4 was not the floor but we also touched new ATL before a weak rebound. Difficult to understand how low they can push the SP, but I’m still convinced we can get a strong up move as we get closer to ER. GLA

2 · Reply

Jhoooon Jul. 14 at 9:27 PM

$FEMY

0 · Reply

Market Cap	9.09M
Revenue (ttm)	2.29M
Net Income (ttm)	-18.63M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-813.54%
Debt to Equity Ratio	0.47

Volume	14,500
Avg Vol	72,597
Day's Range	N/A - N/A
Shares Out	3.02M
Stochastic %K	32%
Beta	-2.13
Analysts	Strong Sell
Price Target	$60.00